Search results
Results from the WOW.Com Content Network
A remortgage (known as refinancing in the United States) is the process of paying off one mortgage with the proceeds from a new mortgage using the same property as security. [1] The term is mainly used commercially in the United Kingdom , though what it describes is not unique to any one country.
PCF holds professional conferences around the U.S. for those involved in the field of cancer. [4] They have funded over 300 scientists and over 430 peer-reviewed research projects across the world in more than 150 leading research institutions nationwide, as well as raised awareness of cancer and educated the public about it through exhibits, the distribution of material, and working with the ...
The Hematological Cancer Research Investment and Education Act of 2001 (Pub. L. 107–172 (text)) amends the Public Health Service Act to allocate funding and establish directed research and education programs targeted at forms of blood cancer, in particular leukemia, lymphoma, and multiple myeloma.
By law CPRIT was established to: "(1) create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer;(2) attract, create, or expand research capabilities of public or private institutions of higher education and other public ...
The Home Affordable Refinance Program (HARP) was created by the Federal Housing Finance Agency in March 2009 to allow those with a loan-to-value ratio exceeding 80% to refinance without also paying for mortgage insurance. Originally, only those with an LTV of 105% could qualify.
The Szent-Györgyi Prize for Progress in Cancer Research, established by the NFCR and named in honor of Albert Szent-Györgyi, Nobel Laureate and co-founder of NFCR, has been awarded annually since 2006 to outstanding researchers whose scientific achievements have expanded the understanding of cancer and whose vision has moved cancer research in new directions.
The basic research division includes programs in cancer regulatory networks and cancer genetics and epigenetics. Programs in the disease-specific division focus on breast cancer, hematological cancer, prostate cancer, and neuro-oncology. The population science division includes cancer epidemiology and prevention, control, and disparities.
The trial is a collaboration among NIH, FDA, SWOG, Foundation Medicine, Friends of Cancer Research, and several pharmaceutical companies. [8] Lung-MAP began enrolling patients on June 15, 2014. [9] By January, 2015, 71 drugs and biologics had been designated as Breakthrough Therapies and the program had facilitated 18 drug approvals. [10]